FDA postpones blood product advisory committee meeting

By Elaine Rigoli

Tampa, Fla., July 14 - The Food and Drug Administration said it cancelled Friday's meeting of the Blood Products Advisory Committee in view of significant public interest in the proposed study and the benefit of public discussion.

The FDA said it will work toward a future meeting where information can be shared with the public.

The FDA had planned to devote the portion of the Blood Products Advisory Committee meeting to consider a proposed clinical trial by the U.S. Naval Medical Research Center of an investigational blood substitute product manufactured by Biopure Corp.

The complexities involved in the development and evaluation of the safety and effectiveness of such products can raise many unique scientific issues, the FDA said.

This meeting was scheduled to provide the advisory committee an opportunity to discuss development plans for this product, and to provide the FDA with additional independent expert input.

Advisory committee meetings that involve early development issues are frequently closed to public participation because confidential commercial information is central to the discussions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.